Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BupiZenge versus lidocaine for oral mucositis pain in head and neck cancer during radiotherapy
2025-524386-24-00Phase 3Authorised
- Sponsor
- OncoZenge
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of bupivacaine + benzydamine in stomatitis (2 arms), sponsored by OncoZenge. Primary endpoint: Total pain reduction from baseline at last day of radiotherapy. Planned start Jun 2026; status: authorised.
02
Drugs
bupivacaine + benzydamine
03
Conditions
stomatitis
Beyond the preview
Go deeper on 2025-524386-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524386-24-00.